Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice
The association of gadolinium-based contrast agents (GBCAs) with nephrogenic systemic fibrosis (NSF) has led to a heightened awareness towards patients’ renal function. Whereas detailed guidelines exist for the use of GBCAs in adult patients, best practice is less well defined in children, especially in the very young. We aimed at identifying current practice with regards to the use of GBCAs in children who undergo Cardiovascular Magnetic Resonance.
We conducted a worldwide survey among cardiac imagers with pediatric expertise. The questionnaire contained 21 questions covering the imagers’ work environments, GBCAs used, monitoring of renal function, and a special emphasis was placed on the practice in neonates.
The survey yielded 70 replies. The single most commonly used GBCA was gadopentetate dimeglumine 34/70 (49%). Among the respondents, the choice of GBCA was more importantly based on availability 26/70 (37%) and approval by a pharmaceutical licensing body that most closely reflects the indication 16/70 (23%) than image quality 7/70 (10%) and side effect profile 8/70 (11%). 55/70 (79%) of respondents performed scans in neonates <1 week of age and 52/55 (95%) of them used GBCA in neonates. 65/70 (93%) respondents at least assess some of their patients’ renal functions. Formula-based estimate of glomerular filtration rate is the most popular assessment method 35/65 (54%). In patients with a glomerular filtration rate < 30 ml/min/1.73 m2 62/70 (89%) of respondents do not administer gadolinium at all. The single most common side effect of gadolinium was noted to be nausea/emesis 34/57 (60%) followed by discomfort at injection site 17/57 (30%).
Cardiac imagers are aware of the immature renal function and physiological differences of their pediatric patients that place them at risk for NSF. Epidemiological data is needed for pediatric cardiovascular licensure of gadolinium compounds and for the creation of practice guidelines which will replace current-day practice based on individual clinical judgment.
- CR Committee on Drugs and Contrast Media [Internet]. 2010. http://www.acr.org/secondarymainmenucategories/quality_safety/contrast_manual.aspx.
- Hunt CH, Hartman RP, Hesley GK: Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009,193(4):1124–1127. CrossRef
- Voth M, Rosenberg M, Breuer J: Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest Radiol 2011,46(11):663–671.
- Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, Furtner J, Born M, Schroder C, Ahlstrom H, Kaiser S, Moritz JD, Kunze CW, Schroff M, Stokland E, Trnkova ZJ, Schultze-Mosgau M, Reif S, Bacher-Stier C, Mentzel HJ: Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol 2009,44(12):776–783. CrossRef
- Lowe L, Kearns G, Wible J: The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 2006,22(12):2515–2524. CrossRef
- Marti-Bonmati L, Vega T, Benito C, Munoz A, Niewei M, Menor F, Neurer K, Encina JL: Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in intants younger than 6 months of age: phase III open multicenter study. Invest Radiol 2000,35(2):141–147. CrossRef
- Forsting M, Palkowitsch P: Prevalence of acute adverse reactions to gadobutrol—A highly concentrated macrocyclic gadolinium chelate: Review of 14,299 patients from observational trials. Eur J Radiol 2010,74(3):e186-e192. CrossRef
- Perazella MA: Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 2008,3(1):67–75. CrossRef
- Cowper SE: Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005,46(4):763–765. CrossRef
- Grobner T: Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006,21(4):1104–1108. CrossRef
- Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C: Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006,20(6):563–576. CrossRef
- Wermuth PJ, Del Galdo F, Jimenez SA: Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009,60(5):1508–1518. CrossRef
- Questions and answers on the review of gadolinium-containing contrast agents [Internet] Euro Med Agency 2010. http://www.ema.europa.eu/docs/en…/gadolinium…/WC500015635.pdf
- Riccabona M, Dacher JN, Olsen ØE, Claudon M, Fotter R: Gadolinium and nephrogenic systemic fibrosis – what to consider for pediatric MR imaging. In Pediatric Uroradiology. 2nd edition. Edited by: Fotter R, Baert AL. Springer; 2008:516–517.
- Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007,2(2):264–267. CrossRef
- Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH: Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011,260(1):105–111. CrossRef
- Bellin MF: MR contrast agents, the old and the new. Eur J Radiol 2006,60(3):314–323. CrossRef
- Nikolaou K, Kramer H, Grosse C, Clevert D, Dietrich O, Hartmann M, Chamberlin P, Assmann S, Reiser MF, Schoenberg SO: High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology 2006,241(3):861–872. CrossRef
- Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND: Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999,34(7):443–448. CrossRef
- Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, Semelka RC: Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Radiology 2009,253(3):689–696. CrossRef
- Boer DP, de Rijke YB, Hop WC, Cransberg K, Dorresteijn EM: Reference values for serum creatinine in children younger than 1 year of age. Pediatr Nephrol 2010,25(10):2107–2113. CrossRef
- CAR national advisory on gadolinium administration and nephrogenic systemic fibrosis [Internet]. 2008. http://www.car.ca/uploads/standardsguidelines/advisory_nsf_en.pdf.
- Filler G, Lepage N: Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003,18(10):981–985. CrossRef
- Delanghe JR: How to estimate GFR in children. Nephrol Dial Transplant 2009,24(3):714–716. CrossRef
- Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Cardiovascular Magnetic Resonance
- Online Date
- August 2012
- Online ISSN
- BioMed Central
- Additional Links